Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

66.58

-0.37 (0.55%)

as of Aug 28, 2026, 8:00:00 pm Market Open.

162 watching

Investor Insights

Aug 30, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Bristol Myers Squibb (BMY) has garnered a mixed set of opinions from various analysts. Some reviewers highlight the company's strong performance in 2023, with a 19% increase in stock price and a robust free cash flow projected to hit $15 billion by 2027. The company is also noted for its attractive dividend yield exceeding 4% and a promising drug pipeline, which could support future growth. However, concerns have been raised regarding the disappointing sales of its Cobenfy drug, leading some experts to reassess their investment positions. Overall, there is a sense of cautious optimism about the potential for recovery if the growth portfolio can continue to outperform the legacy products.

Consensus

Mixed

Valuation

Undervalued

Similar

EliLilly,LLY

DON'T BUY

Had many problems in the past with pipeline, patent lawsuits. Now reaching the point where it is a turnaround story. Doesn't see anything happening in the near term that will boost their profitability or the outlook of the company.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Lost its patent protection on its major drug, Plavix. Looking at other companies where they have lost their patent rights, there is a major sell off, but it takes a while before the company can replace the lost revenue.

HOLD

This would be in that category of very large US companies that haven't done much for a while. Starting to look interesting. Valuation is not bad. Good place to hide defensively.

DON'T BUY

From a technical point of view, it does not look good. Could see downside risk to about the $20 level. Fair market value is about $40/45, but it is technically weak. Would be nervous in a recession.

DON'T BUY

In the major pharmaceutical companies you see low multiple stocks yielding 4/5% and it may look like a good bet. Use caution as it is a risky bet. Revenues over the last couple of years have been under pressure. On this one, about 3/4 of their earnings is being paid out in dividends.

PAST TOP PICK

(A Top Pick Feb 23/05. Up 1.5%.) Has a fat dividend over 5%. Was troubled with patents coming off some major drugs. That's out of the stock now. Decent pipeline.

PAST TOP PICK

(Past Top Pick Nov 3/04. Up 1%.) Likes the health care sector and the drug makers have been under fire for years and this company has weathered the storm quite well. Decent dividend yield. Solid earnings.

TOP PICK

A big boring drug company which has not performed well for the last few years. Has been going sideways. Yielding 4.6%. He's waiting for the new pipeline to kick in. It's an exciting pipeline and they have some new drugs out.

BUY

Pharmaceutical stocks in general have been poor performers and valuations have become more reasonable, so is probably OK to start looking at them. Prefers Bristol Myers as you get a nice size dividend as they wait for a pick up.

BUY

Yields over 5%. Had problems a few years ago, but is beginning to turn them around.

TOP PICK

Drug stocks all declined in sympathy when Merck pulled their Vioxx. Dividend yield of nearly 5%.

BUY

Wouldn't invest in pharmaceuticals, but this company has a good global diversification.

DON'T BUY

Has a very large dividend and investors may have bought the stock for this reason but not sure how sustainable the dividend is. In a legal situation with a patent dispute. Revenue growth next year is expected to be minus. Very expensive.

DON'T BUY

The drug sector has been going through a selloff for many months. He can find nothing in this sector that is performing well.

BUY

Probably better positioned than some of the other pharmaceutical companies in terms of product life cycle. Probably a pretty good buy at this price.

Showing 166 to 180 of 222 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Raymond James

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Bristol Myers Squibb (BMY)